Invokana 100 mg and 300 mg film-coated tablets

  • Name:

    Invokana 100 mg and 300 mg film-coated tablets

  • Company:
    info
  • Active Ingredients:

    Canagliflozin hemihydrate

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 03/07/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 3/7/2020

Click on this link to Download PDF directly

Mundipharma Pharmaceuticals Limited - Formerly Napp Laboratories

mundi_logo

Company Products

Medicine NameActive Ingredients
Medicine Name Adizem-SR Capsules Active Ingredients Diltiazem Hydrochloride
Medicine Name ADIZEM-XL Capsules Active Ingredients Diltiazem Hydrochloride
Medicine Name BuTrans 15 microgram/hour transdermal patches Active Ingredients Buprenorphine
Medicine Name BuTrans transdermal patches Active Ingredients Buprenorphine
Medicine Name Flutiform 50 microgram/5 microgram, 125 microgram/5 microgram and 250 micorgram/10 microgram per metered dose pressurised inhalation, suspension. Active Ingredients Fluticasone Propionate, Formoterol fumarate dihydrate
Medicine Name Flutiform K-haler 50 microgram /5 microgram, 125 microgram /5 microgram per actuation pressurised inhalation, suspension. Active Ingredients Fluticasone Propionate, Formoterol fumarate dihydrate
Medicine Name Herzuma 150 mg and 420 mg powder for concentrate for solution for infusion Active Ingredients Trastuzumab
Medicine Name Invokana 100 mg and 300 mg film-coated tablets Active Ingredients Canagliflozin hemihydrate
Medicine Name MST Continus Suspension Active Ingredients Morphine sulfate
Medicine Name MST Continus Tablets Active Ingredients Morphine sulfate
Medicine Name Nyxoid 1.8 mg nasal spray Active Ingredients Naloxone Hydrochloride dihydrate
Medicine Name OxyContin prolonged release tablets Active Ingredients Oxycodone Hydrochloride
Medicine Name OxyNorm 10 mg/ml solution for Injection or Infusion Active Ingredients Oxycodone Hydrochloride
Medicine Name OxyNorm 50 mg/ml, solution for injection or infusion Active Ingredients Oxycodone Hydrochloride
Medicine Name OxyNorm Capsules Active Ingredients Oxycodone Hydrochloride
Medicine Name OxyNorm Concentrate Active Ingredients Oxycodone Hydrochloride
Medicine Name OxyNorm Dispersa 5, 10, 20 mg orodispersible tablets Active Ingredients Oxycodone Hydrochloride
Medicine Name OxyNorm liquid 1 mg/ml oral solution Active Ingredients Oxycodone Hydrochloride
Medicine Name PALLADONE Capsules Active Ingredients Hydromorphone Hydrochloride
Medicine Name Palladone SR Capsules Active Ingredients Hydromorphone Hydrochloride
Medicine Name Pelmeg 6 mg solution for injection in pre-filled syringe Active Ingredients Pegfilgrastim
Medicine Name PHYLLOCONTIN CONTINUS Tablets Active Ingredients Aminophylline Hydrate
Medicine Name SEVREDOL Tablets Active Ingredients Morphine sulfate
Medicine Name Targin 15 mg/7.5 mg and 30 mg/15 mg prolonged-release tablets Active Ingredients Naloxone Hydrochloride dihydrate, Oxycodone Hydrochloride
Medicine Name Targin 5/2.5mg, 10mg/5mg, 20mg/10mg and 40/20mg prolonged release tablets Active Ingredients Naloxone Hydrochloride dihydrate, Oxycodone Hydrochloride
1 - 0 of 30 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 3 July 2020 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 4 - possible side effects
  • Change to other sources of information section

Free text change information supplied by the pharmaceutical company

Section 1 - Addition of statement 'It also helps to slow down deterioration of kidney function in patients with T2DM by a mechanism beyond blood glucose lowering.'

Section 4 - Addition of warning 'Diabetic ketoacidosis may occur more frequently as the kidney function gets worse.'

Update to local representative details.

Updated on 3 July 2020 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2 – Removal of sodium warnings.

Section 4.1 – Addition of cross references to section 4.4, 4.5 and 5.1 in relation to renal events.

Section 4.2 – Addition of posology for the treatment of diabetic kidney disease. Updates to dose adjustment recommendations according to eGFR.

Section 4.4 – Amendment to warnings in relation to eGFR. Addition of warning in relation to risk of diabetic ketoacidosis in patients with decreased renal function. Amendment to warning in relation to lower limb amputation following outcome of the CREDENCE study. Addition of sodium warning in line with the updated Annex to the guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’.

Section 4.8 – Amendment to data on patient exposure as a result of the CREDENCE study. Updated data in relation to diabetic ketoacidosis, lower limb amputation, volume depletion, bone fracture and renal impairment following outcome of the CREDENCE study.

Section 5.1 – Addition of further information on the mechanism of action. Addition of section on renal outcomes in the CREDENCE study.

Updated on 10 February 2020 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 - Addition of photosensitivity and UTI as potential adverse events.

Updated on 10 February 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Addition of photosensitivity and UTI as potential adverse events.

Updated on 3 December 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Addition of information on monitoring of patients with diabetic ketoacidosis in section 4.4.

Updated on 6 March 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 6 March 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Texts updated following implementation of product class labelling effect regarding the possible side effect  - Fournier’s gangrene

Updated on 30 November 2018 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Shelf-life changed form 2 years to 3 years

Updated on 12 September 2018 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Removal of Black Inverted Triangle

Updated on 12 September 2018 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Removal of the Black Triangle

Update to document including changes to 

4.1       Therapeutic indications

4.4       Special warnings and precautions for use

Lower limb amputations

4.8       Undesirable effects

Summary of the safety profile

Description of selected adverse reactions

 

5.1       Pharmacodynamic properties

 

Lower limb amputation

Adverse reactions related to volume depletion

Genital mycotic infections

Bone fracture

Special populations

Renal impairment

Clinical efficacy and safety

Blood pressure

Cardiovascular outcomes

 All‑cause mortality

Heart failure requiring hospitalization

Renal Endpoints

 

9.         DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of latest renewal: 26 July 2018

Updated on 9 August 2018 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 3 - dose and frequency
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision
  • Removal of Black Inverted Triangle

Updated on 9 August 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The black triangle has been removed from the beginning of the SPC.

Section 4.2

estimated glomerular filtration rate (   )’ has been added to the first paragraph in section 4.2

Special populations’ subheading added to the section.

Studies’ replaced ‘trials’ at several places within the section.

‘careful monitoring’ replaces ‘caution’

Section 4.5

‘medicinal product’ replacing ‘drug’ within the second paragraph of section 4.5

‘medicinal product’ replacing ‘drug’ within subheading ‘…/Laboratory test interference’

Section 5.1

‘other’ removed from the first sentence of section 5.1

Older patients’ replace ‘elderly’

Section 6.1

‘anhydrous’ removed from ‘lactose anhydrous’ within tablet core excipients

‘Polyvinyl-alcohol’ has become ‘Poly(vinyl alcohol)

Section 8

‘Film-coated’ added to section

Section 9

‘Date of latest renewal: 26 July 2018 ‘  added to section 9

Section 10

Date of revision updated to ’26 July 2018’                      

 

Updated on 22 June 2018 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2

Each tablet contains less than 1 mmol sodium (23 mg), and is essentially sodium-free.’ This text has been added to ‘Excipient(s) with known effect’ section for both strengths.

 

Section 4.4

This text below has be removed from the section:

General

Invokana has not been studied in patients with type 1 diabetes and is therefore not recommended for use in these patients

Invokana should not be used for the treatment of diabetic ketoacidosis as it is not effective in this setting.’

The text in bold has been added to the section and the text in strikethrough has been removed from the section:

The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp total lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product medicine.

 

Section 5.1

The text in bold has been added to the section and the text in strikethrough has been removed from the section:

‘A total of 10,285 10,501 patients with type 2 diabetes participated in nine ten double blind, controlled clinical efficacy and safety studies conducted to evaluate the effects of Invokana on glycaemic control. The racial distribution was 72% White, 16% Asian, 4 5% Black, and 8% other groups. 16 17% of patients were Hispanic. Approximately 58% of patients were male. Patients had an overall mean age of 59.6 59.5 years (range 21 years to 96 years), with 3,082 3,135 patients ≥ 65 years of age and 510 513 patients ≥ 75 years of age. 58% of patients had a body mass index (BMI) ≥ 30 kg/m2….’

The text below has been added to section 5.1:

‘Furthermore, canagliflozin was studied as triple therapy with metformin and sitagliptin and dosed with a titration regimen, using a starting dose of 100 mg and titrated to 300 mg as early as week 6 in patients requiring additional glycaemic control who had appropriate eGFR and were tolerating canagliflozin 100 mg (table 2). Canagliflozin dosed with a titration regimen produced clinically and statistically significant (p < 0.001) results relative to placebo in glycaemic control, including HbA1c and change from baseline fasting plasma glucose (FPG), and a statistically significant (p < 0.01) improvement in the percentage of patients achieving HbA1c < 7%. In addition, reductions in body weight and systolic blood pressure relative to placebo were observed.’

Within table 2 there has been this change below:

‘Difference from placebo (adjusted mean)

(97.5 95 % CI) ‘

There has been this addition to table 2

 

There has been an addition to the footnote of table 2:

‘ e           Canagliflozin 100 mg titrated to 300 mg

 F             p<0.01 compared to placebo

G             90.7% of subjects in the canagliflozin untitrated to 300 mg.’

 

This text and table below have been added to the section:

 ‘Canagliflozin as initial combination therapy with metformin

Canagliflozin was evaluated in combination with metformin as initial combination therapy in patients with type 2 diabetes failing diet and exercise. Canagliflozin 100 mg and canagliflozin 300 mg in combination with metformin XR resulted in a statistically significant greater improvement in HbA1C compared to their respective canagliflozin doses (100 mg and 300 mg) alone or metformin XR alone (table 4).

Addition of table 4

 


Section 10

Date of revision updated to ‘15 March 2018’

 

Updated on 22 June 2018 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to date of revision

Updated on 2 January 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 2 January 2018 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Change in co-marketing arrangement

Updated on 18 September 2017 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 5.1

ATC code changed to A10BK02.

Updated on 18 September 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 8 May 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4: Revision to include class labelling text on diabetic ketoacidosis: “Rare cases of diabetic ketoacidosis (DKA), including life-threatening and fatal cases, have been reported in patients treated with SGLT2 inhibitors, including canagliflozin.”

 

Section 10: Commission Decision of 28 April 2017

Updated on 4 May 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 27 April 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4: addition of information on lower limb amputations

Section 4.8: addition of “lower limb amputations” as adverse reaction under frequency “uncommon”

Section 10: Commission Decision date of 20 April 2017

Updated on 24 April 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 3 February 2017 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 13 October 2016 SmPC

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

$0Paediatric population$0A paediatric Phase 1 studyexamined the pharmacokinetics and pharmacodynamics of canagliflozin in childrenand adolescents ≥ 10 to < 18 years of age with type 2diabetes mellitus. The observed pharmacokinetic and pharmacodynamic responseswere consistent with those found in adult subjects.

Updated on 31 August 2016 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8: Addition of anaphylactic reaction, frequency rare. Angioedema frequency changed from not known to rare.$0$0$0$0Section 5.2: Distribution$0$0The mean steady‑state volume of distribution (Vd) of canagliflozin following a single intravenous infusion in healthy subjects was 83.5119 litres, suggesting extensive tissue distribution.$0

Updated on 30 August 2016 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 6 May 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4: Addition of information regarding Diabetic Ketoacidosis (DKA)$0Section 4.8: Addition of Diabetic Ketoacidosis as a rare side effect$0

Updated on 4 May 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 22 December 2015 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Addition of uncommon adverse reaction: Renal failure (mainly in the context of volume depletion)

Updated on 22 December 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 26 August 2015 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 26 August 2015 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Addition of adverse reaction ‘angioedema’ under “not known” frequency. Addition of adverse reactions pyelonephritis and urosepsis for existing adverse reaction ‘Urinary tract infection’

Updated on 29 July 2014 PIL

Reasons for updating

  • New PIL for new product

Updated on 29 July 2014 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided